Daniel N. Streblow, Ph.D.

  • Associate Professor, VGTI-Vaccine and Gene Therapy Institute
  • Molecular Microbiology and Immunology Graduate Program, School of Medicine
  • Program in Molecular and Cellular Biosciences, School of Medicine

Biography

Dr. Daniel Streblow received his B.S. in Pharmacology/Toxicology from the University of Wisconsin-Madison in 1992. He graduated from University of Wisconsin-Madison with a Ph.D. in Viral Pathogenesis in 1997. Dr. Streblow received a NIH post-doctoral fellowship and worked with Dr. Jay A. Nelson in the Department of Molecular Microbiology and Immunology at Oregon Health & Science University. He is currently an Associate Scientist at the Vaccine and Gene Therapy Institute and Research Assistant Professor at the Department of Molecular Microbiology and Immunology.

The focus of the Streblow laboratory is on defining the role of human cytomegalovirus (HCMV) in the development of vascular disease and chronic rejection of organ allografts. The role of CMV in these diseases is still uncharacterized. Dr. Streblow's lab studies the following topics: 1) Determining the mechanisms of HCMV-accelerated vascular disease through identification of the viral genes expressed during these diseases using a HCMV microarray chip developed by Dr. Streblow's laboratory in combination with the Shared Microarray Core at VGTI. Once identified, the function of these viral genes will be examined using in vitro and in vivo models of CMV-accelerated vascular disease. 2) Determining the mechanisms of CMV-accelerated vascular disease in both mouse models of atherosclerosis and rat organ transplantation models using a DNA microarray approach. The Streblow lab in conjunction with Dr. Susan Orloff’s laboratory at OHSU has determined RCMV in vivo gene expression in infected rats and has begun functional studies of these genes. 3) Determine viral and host gene expression during the development of atherosclerosis and transplant vascular sclerosis, the vascular lesion associated with chronic allograft rejection 4) determining the mechanisms of viral acceleration of chronic allograft rejection from latently infected donor, which is the most common cause of HCMV-associated disease in transplant patients associated with expression during the different stages of viremia associated with CMV including 5) Determining the function of CMV-encoded chemokine receptors in the context of viral pathogenesis and acceleration of vascular disease. Dr. Streblow's lab has also generated a rhesus macaque (RM) chikungunya virus (CHIKV) infection animal model to identify correlates of CHIKV pathogenesis and to test novel antivirals and vaccines. They are working on developing a Zika virus RM model.

Education

  • B.S., 1992, University of Wisconsin
  • Ph.D., 1997, University of Wisconsin

Areas of interest

  • CMV pathogenesis and transplantation

Publications

Selected publications

  • Hirsch AJ, Smith JL, Haese NN, Broeckel RM, Parkins CJ,Kreklywich C, DeFilippis VR, Denton M, Smith PP, Messer WB, Colgin LM, DucoreRM, Grigsby PL, Hennebold JD, Swanson T, Legasse AW, Axthelm MK, MacAllister R,Wiley CA, Nelson JA, Streblow DN. Zika Virus infection of rhesus macaques leadsto viral persistence in multiple tissues. PLoS Pathog. 2017 Mar9;13(3):e1006219. doi: 10.1371/journal.ppat.1006219. [PMID: 28278237]
  • Haese NN, Broeckel RM, Hawman DW, Heise MT, Morrison TE,Streblow DN. Animal Models of Chikungunya Virus Infection and Disease. J InfectDis. 2016 Dec 15;214(suppl 5):S482-S487. [PMID: 27920178]
  • Burwitz BJ, Malouli D, Bimber BN, Reed JS, Ventura AB,Hancock MH, Uebelhoer LS, Bhusari A, Hammond KB, Espinosa Trethewy RG, Klug A,Legasse AW, Axthelm MK, Nelson JA, Park BS, Streblow DN, Hansen SG, Picker LJ,Früh K, Sacha JB. Cross-Species Rhesus Cytomegalovirus Infection of CynomolgusMacaques. PLoS Pathog. 2016 Nov 9;12(11):e1006014. doi:10.1371/journal.ppat.1006014.[PMID: 27829026]
  • Caviness K, Bughio F, Crawford LB, Streblow DN, Nelson JA,Caposio P, Goodrum F. Complex Interplay of the UL136 Isoforms BalancesCytomegalovirus Replication and Latency. MBio. 2016 Mar 1;7(2):e01986. doi:10.1128/mBio.01986-15.[PMID: 26933055]

Publications

  • {{ pub.journalAssociation.journal.name.text[0].value }}
    1. {{ person.name.firstName }} {{ person.name.lastName }}